Telesis Therapeutics is an early stage biopharmaceutical company. We accelerate the development of breakthrough discoveries acquired from research institutions into medicines for patients. We currently focus on drug development and commercialization in oncology. We acquire early stage assets with issued or pending IP and positive biologic signals. Our business model encompasses discovery research, IND enabling studies, and clinical development. We identify, develop, de-risk, and commercialize assets, or we strategically partner or license our assets for later stage development and commercialization. We have acquired our first oncology asset, TTL-315, a small molecule antimetabolite to treat solid tumors. The published preclinical data for this asset, includes: cell, animal, and early toxicology. This molecule has a global IP portfolio. We seek public and private funding to support further research and development, and partnerships and collaborations. Our recent collaboration with the NCI's Fredrick National Laboratory for Cancer Research (FNLCR) is significant. We have executed a cooperative research and development agreement (CRADA) with the FNLCR. The preclinical development program and resulting research will help prepare TTL-315 for clinical translation. Our initial therapeutic target is for the treatment of patients with solid tumors, specifically for pancreatic ductal adenocarcinoma (PDAC). This deadly cancer has a high unmet medical need, and we will secure an Orphan Drug designation. This will offer TTL-315 extended patent life, and an opportunity for accelerated regulatory and development pathways. Follow on indications will include, small cell lung and colorectal cancers.